For the first time, three respiratory vaccines and one Tdap combination vaccine are now approved for use by late-stage pregnant women.
On September 22, 2023, members of the U.S. CDC's Advisory Committee on Immunization Practices (ACIP) voted 11-1 to recommend a maternal respiratory syncytial virus (RSV) vaccine for pregnant women during 32 through 36 weeks gestation to protect their newborn from severe RSV illness.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
